Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

Merck KGaA's lupus drug enpatoran fails Phase 2 trial, Zymeworks halts ZW220 development, Tris Pharma's cebranopadol succeeds in pain trial, ARS Pharma's neffy gets pediatric approval ...

Find insight on Merck KGaA, Bayer, Jazz Pharmaceuticals and the use of AI in China’s healthcare sector in the latest Market ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

Varda Space Industries achieved the first successful commercial space reentry in Australia, a milestone for the industry. Varda's co-founder and president, Delian Asparouhov, joins Josh Lipton on ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.